The AP1-dependent secretion of galectin-1 by Reed–Sternberg cells fosters immune privilege in classical Hodgkin lymphoma
Top Cited Papers
Open Access
- 7 August 2007
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 104 (32) , 13134-13139
- https://doi.org/10.1073/pnas.0706017104
Abstract
Classical Hodgkin lymphomas (cHLs) contain small numbers of neoplastic Reed–Sternberg (RS) cells within an extensive inflammatory infiltrate that includes abundant T helper (Th)-2 and T regulatory (T reg ) cells. The skewed nature of the T cell infiltrate and the lack of an effective host antitumor immune response suggest that RS cells use potent mechanisms to evade immune attack. In a screen for T cell-inhibitory molecules in cHL, we found that RS cells selectively overexpressed the immunoregulatory glycan-binding protein, galectin-1 (Gal1), through an AP1-dependent enhancer. In cocultures of activated T cells and Hodgkin cell lines, RNAi-mediated blockade of RS cell Gal1 increased T cell viability and restored the Th1/Th2 balance. In contrast, Gal1 treatment of activated T cells favored the secretion of Th2 cytokines and the expansion of CD4 + CD25 high FOXP3 + T reg cells. These data directly implicate RS cell Gal1 in the development and maintenance of an immunosuppressive Th2/T reg -skewed microenvironment in cHL and provide the molecular basis for selective Gal1 expression in RS cells. Thus, Gal1 represents a potential therapeutic target for restoring immune surveillance in cHL.Keywords
This publication has 47 references indexed in Scilit:
- Galectin-1 mediated suppression of Epstein-Barr virus–specific T-cell immunity in classic Hodgkin lymphomaBlood, 2007
- Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomasProceedings of the National Academy of Sciences, 2007
- Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapyProceedings of the National Academy of Sciences, 2006
- Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen–specific CD8+ T-cell function in Hodgkin lymphoma patientsBlood, 2006
- IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivoBlood, 2006
- BAL1 and BBAP Are Regulated by a Gamma Interferon-Responsive Bidirectional Promoter and Are Overexpressed in Diffuse Large B-Cell Lymphomas with a Prominent Inflammatory InfiltrateMolecular and Cellular Biology, 2006
- Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approachBlood, 2005
- Presentation of Galectin-1 by Extracellular Matrix Triggers T Cell DeathJournal of Biological Chemistry, 2004
- AP-1 blockade inhibits the growth of normal and malignant breast cellsOncogene, 2001
- Highly specific localization of promoter regions in large genomic sequences by PromoterInspector: a novel context analysis approachJournal of Molecular Biology, 2000